Clinical Trial: Primary Prevention Long-term Registry Study. Major Cardiovascular Events/Survival Analysis 2010-2022 on Patients With PAP Treated Obstructive Sleep Apnea (OSA) and Hypertension (HT). Comparison Against HT Alone , OSA Alone and Healthy Controls. Evaluation of Mitigating Effect of PAP Treatment.

U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT06930989) titled 'Primary Prevention Long-term Registry Study. Major Cardiovascular Events/Survival Analysis 2010-2022 on Patients With PAP Treated Obstructive Sleep Apnea (OSA) and Hypertension (HT). Comparison Against HT Alone , OSA Alone and Healthy Controls. Evaluation of Mitigating Effect of PAP Treatment.' on April 08.

Brief Summary: Hypertension and obstructive sleep apnea (OSA) are both common conditions that independently increase the risk cardiovascular disease including atrial fibrillation, ischemic heart disease, heart failure and stroke. OSA is also an independent promoter of hypertension development and poorly controlled hypertension i...